ArticleAdvanced nanobiomed research2025
Detection of Estrogen Receptor Status in Breast Cancer Cytology Samples by an Optical Nanosensor.
Article in Advanced nanobiomed research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Screening molecular recognition element-based SWCNT optical sensors for the inflammatory cytokine TNF-α.Biosensors & bioelectronics · 2026Article
- High-Throughput SWCNT NIR-II Spectroscopy Enables Cell and In Vivo Applications.ACS nanoscience Au · 2026Article
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Optical Spectral Fingerprinting Enables Sensitive Detection of Anthracycline Chemotherapeutics in Synthetic Clinical Biofluids.Nano letters · 2026Article
- Optical Spectral Fingerprinting Enables Sensitive Detection of Anthracycline Chemotherapeutics in Synthetic Clinical Biofluids.bioRxiv : the preprint server for biology · 2026Article
- Rational Design of Optical Single-Walled Carbon Nanotube-Based Nanosensors with Biological Recognition Elements.Advanced sensor research · 2026Article
- High-throughput SWCNT NIR-II screening enables cell andbioRxiv : the preprint server for biology · 2026Article
- Screening Molecular Recognition Element-Based SWCNT Optical Sensors for the Inflammatory Cytokine TNF-α.bioRxiv : the preprint server for biology · 2026Article
- Multiplexed Molecularly-Specific SWCNT Cytokine Sensing is Enabled and Enhanced by Amine-Functionalized DNA Aqueous Two-Phase Extraction.bioRxiv : the preprint server for biology · 2025Article
- Effect of Polyelectrolytes on the Photoluminescence of Single-Walled Carbon Nanotubes-Experimental and Simulation Studies.ACS omega · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer is a substantial source of morbidity and mortality worldwide. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are the primary biomarkers which inform breast cancer treatment. Although endocrine therapy for ER+ patients is widely available, there is a need for increased access to low cost, rapid and accurate ER testing methods. In this work, we designed a near-infrared optical nanosensor using single-walled carbon nanotubes (SWCNT) as the transducer and an anti-ERα antibody as the recognition element. We evaluated the sensor in vitro prior to testing with 26 breast cancer samples which were collected by scraping the cut surface of fresh, surgically resected tumors. 20 samples were ER+, and 6 ER-, representing 13 unique patients. We found the nanosensor can differentiate ER- from ER+ patient biopsies through a shift in its center wavelength upon sample addition. Receiver operating characteristic area under the curve analyses determined that the strongest classifier with an AUC of 0.94 was the (7,5) SWCNT after direct incubation and measurement, and without further processing. We anticipate that further testing and development of this nanosensor may push its utility toward field-deployable, rapid ER subtyping with potential for additional molecular marker profiling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.